"Busulfan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
| Descriptor ID |
D002066
|
| MeSH Number(s) |
D02.033.455.125.125 D02.455.326.146.100.050.500.100 D02.886.645.600.055.050.510.100
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Busulfan".
Below are MeSH descriptors whose meaning is more specific than "Busulfan".
This graph shows the total number of publications written about "Busulfan" by people in this website by year, and whether "Busulfan" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2017 | 6 | 1 | 7 |
| 2018 | 4 | 3 | 7 |
| 2019 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Busulfan" by people in Profiles.
-
Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (=60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT. Bone Marrow Transplant. 2020 04; 55(4):729-739.
-
Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2019 12; 54(12):2013-2019.
-
Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience. Haematologica. 2019 09; 104(9):1798-1803.
-
Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation. Int J Hematol. 2019 Feb; 109(2):197-205.
-
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. Am J Hematol. 2018 10; 93(10):1211-1219.
-
Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2018 11; 24(11):2224-2232.
-
Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. Blood Adv. 2018 06 12; 2(11):1198-1206.
-
Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT. Am J Hematol. 2018 07; 93(7):859-866.
-
Monitoring of Busulphan Concentrations in Children Undergone Hematopoietic Stem Cell Transplantation: Unicentric Experience over 10 years. Eur J Drug Metab Pharmacokinet. 2018 Apr; 43(2):173-181.
-
Outcomes of Children with Hemophagocytic Lymphohistiocytosis Given Allogeneic Hematopoietic Stem Cell Transplantation in Italy. Biol Blood Marrow Transplant. 2018 06; 24(6):1223-1231.